Current Report Filing (8-k)
January 19 2021 - 7:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 19, 2021
Taysha Gene Therapies, Inc.
(Exact name of registrant as specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-39536
|
|
84-3199512
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
2280 Inwood Road
Dallas, Texas
|
|
75235
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(214) 612-0000
(Registrants Telephone Number, Including Area Code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.00001 par value
|
|
TSHA
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 8.01 Other Events.
On January 19, 2021, Taysha Gene Therapies, Inc. (the Company) issued a press release entitled Taysha Gene Therapies
Receives Rare Pediatric Disease Designation and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency. The full text of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Taysha Gene Therapies, Inc.
|
|
|
|
|
Dated: January 19, 2021
|
|
|
|
By:
|
|
/s/ Kamran Alam
|
|
|
|
|
|
|
Kamran Alam
|
|
|
|
|
|
|
Chief Financial Officer
|
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From May 2024 to Jun 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2023 to Jun 2024